Francisco Armero Gutiérrez
Private Equity Investor at Clave Mayor SGEIC SA
Francisco Armero Gutiérrez active positions
| Companies | Position | Start | End |
|---|---|---|---|
Clave Mayor SGEIC SA
 Clave Mayor SGEIC SA Investment ManagersFinance Clave Mayor SGEIC SA (Clave Mayor) is an independent private equity firm founded in 2002. The firm is headquartered in Pamplona with additional offices in Valencia, Spain. | Private Equity Investor | 30/04/2012 | - |
Career history of Francisco Armero Gutiérrez
Former positions of Francisco Armero Gutiérrez
| Companies | Position | Start | End |
|---|---|---|---|
HepaCyl Therapeutics SL
 HepaCyl Therapeutics SL BiotechnologyHealth Technology HepaCyl Therapeutics SL is a holding company engaged in the design and development of biomedical products for the detection and treatment of hepatitis and cancer. The company was founded on March 5, 2010 and is headquartered in Valladolid, Spain. | Director/Board Member | - | 31/01/2016 |
Traslational Cancer Drugs Pharma SL
 Traslational Cancer Drugs Pharma SL BiotechnologyHealth Technology Traslational Cancer Drugs Pharma SL engages in the discovery and development of therapeutic solutions for the treatment of cancer. Its TCD-717 choline kinase alpha inhibitor is an intravenously-administered small molecule designed to target cancer cells. It also provides technology in-licensing and out-licensing services. The company was founded by Juan Carlos San Juan on July 29, 2005 and is headquartered in Valladolid, Spain. | Director/Board Member | - | - |
Mevion Technology SL
 Mevion Technology SL Miscellaneous Commercial ServicesCommercial Services Mevion Technology SL is a holding company engaged in the provision of industrial ionization services, using electron beam accelerators. This technology finds applications in the medical, pharmaceutical, electronics, and aerospace sectors, and allows for product sterilization, sanitation, crosslinking, and depolymerization. It also provides technical consulting, logistics, and microbiological analysis services. The company was founded on September 11, 2009 and is headquartered in Olvega, Spain. | Director/Board Member | - | - |
Training of Francisco Armero Gutiérrez
| University of Valladolid | Undergraduate Degree |
| Instituto de Empresa SL | Graduate Degree |
| Universida de Alcalá de Henares | Graduate Degree |
Statistics
International
| Spain | 8 |
Operational
| Director/Board Member | 3 |
| Graduate Degree | 2 |
| Private Equity Investor | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 4 |
|---|---|
Clave Mayor SGEIC SA
Clave Mayor SGEIC SA Investment ManagersFinance Clave Mayor SGEIC SA (Clave Mayor) is an independent private equity firm founded in 2002. The firm is headquartered in Pamplona with additional offices in Valencia, Spain. | Finance |
HepaCyl Therapeutics SL
HepaCyl Therapeutics SL BiotechnologyHealth Technology HepaCyl Therapeutics SL is a holding company engaged in the design and development of biomedical products for the detection and treatment of hepatitis and cancer. The company was founded on March 5, 2010 and is headquartered in Valladolid, Spain. | Health Technology |
Mevion Technology SL
Mevion Technology SL Miscellaneous Commercial ServicesCommercial Services Mevion Technology SL is a holding company engaged in the provision of industrial ionization services, using electron beam accelerators. This technology finds applications in the medical, pharmaceutical, electronics, and aerospace sectors, and allows for product sterilization, sanitation, crosslinking, and depolymerization. It also provides technical consulting, logistics, and microbiological analysis services. The company was founded on September 11, 2009 and is headquartered in Olvega, Spain. | Commercial Services |
Traslational Cancer Drugs Pharma SL
Traslational Cancer Drugs Pharma SL BiotechnologyHealth Technology Traslational Cancer Drugs Pharma SL engages in the discovery and development of therapeutic solutions for the treatment of cancer. Its TCD-717 choline kinase alpha inhibitor is an intravenously-administered small molecule designed to target cancer cells. It also provides technology in-licensing and out-licensing services. The company was founded by Juan Carlos San Juan on July 29, 2005 and is headquartered in Valladolid, Spain. | Health Technology |
